Makena: New Randomized Trial May Only Happen If Drug Stays On The US Market

Covis declines to commit to conducting another randomized, placebo-controlled trial if the preterm birth prevention drug is withdrawn, saying currently available data from physician and patient surveys suggest a new study may not be feasible if approval is pulled.

Makena mist
Covis declined to offer a clear view on whether it would do another trial in Makena were removed from the market. • Source: Shutterstock

Covis Pharma has declined to commit to conducting a new randomized, placebo-controlled trial Makena (hydroxyprogesterone caproate injection, also known as 17-OHPC or 17P) if the US Food and Drug Administration orders the preterm birth prevention drug off the market.

At the second day of a hearing on the Center for Drug Evaluation and Research’s proposal to withdraw Makena’s accelerated...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Review Pathways

More from Pathways & Standards